Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018220537) ADJUVANT SUPPLEMENT FOR ONCOLOGICAL PATIENTS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/220537 International Application No.: PCT/IB2018/053826
Publication Date: 06.12.2018 International Filing Date: 30.05.2018
IPC:
A23L 33/10 (2016.01) ,A61K 45/06 (2006.01) ,A61K 31/191 (2006.01) ,A61K 31/202 (2006.01) ,A61K 31/401 (2006.01) ,A23L 33/105 (2016.01) ,A23L 33/115 (2016.01) ,A23L 33/12 (2016.01) ,A23L 33/15 (2016.01) ,A23L 33/155 (2016.01) ,A23L 33/16 (2016.01) ,A23L 33/175 (2016.01)
[IPC code unknown for A23L 33/10]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
185
Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19
Carboxylic acids, e.g. valproic acid
191
Acyclic acids having two or more hydroxy groups, e.g. gluconic acid
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
185
Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19
Carboxylic acids, e.g. valproic acid
20
having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
202
having three or more double bonds, e.g. linolenic acid
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
40
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
401
Proline; Derivatives thereof, e.g. captopril
[IPC code unknown for A23L 33/105][IPC code unknown for A23L 33/115][IPC code unknown for A23L 33/12][IPC code unknown for A23L 33/15][IPC code unknown for A23L 33/155][IPC code unknown for A23L 33/16][IPC code unknown for A23L 33/175]
Applicants:
DELL'ORTI, Massimo [IT/IT]; IT
RAVERA, Ugo [IT/IT]; IT
Inventors:
DELL'ORTI, Massimo; IT
DELL'ORTI, Alexander; IT
Agent:
RASTELLI, Franco; IT
Priority Data:
10201700005900630.05.2017IT
Title (EN) ADJUVANT SUPPLEMENT FOR ONCOLOGICAL PATIENTS
(FR) COMPLÉMENT D'ADJUVANT POUR PATIENTS ONCOLOGIQUES
Abstract:
(EN) A supplement for sequential adjuvant oncological treatment, comprising a Kit (1) of substances suitable to produce ROS with the aim of selective biological damage for cancer cells, a Kit (2) of substances having functionalities of differentiation and of apoptosis of the neoplastic cells that survived the biological damage induced by the treatment with aforesaid Kit (1), and a Kit (3) of substances that perform the function of metastatic blockage of the neoplastic cells that survived the treatment with the aforesaid Kit (2). In relation to known radio and chemotherapy treatments in the cancer field, the supplement of the invention allows an increase in the effectiveness of the therapy, significantly improving the therapeutic results obtained with or without conventional therapies and the quality of life of the patient, with an increase in survival. The administration of this supplement, while keeping the disease under control, would prevent massive tumour lysis syndrome, often resulting from chemo/radiotherapy, leading to severe functional failure of excretory organs (kidneys/liver) and cardiac failure, causing the death of the patient. Obtaining cancer as a stable chronic disease under control would prevent the lethal consequences caused by massive neoplastic destruction, increasing survival with excellent quality of life.
(FR) La présente invention concerne un complément pour un traitement oncologique à adjuvant séquentiel, comprenant un kit (1) de substances adaptées à produire des ROS dans le but de causer un dommage biologique sélectif à des cellules cancéreuses, un kit (2) de substances présentant des fonctionnalités de différentiation et d'apoptose des cellules néoplasiques qui ont survécu aux dommages biologiques causés par le traitement par le kit précité (1), et un kit (3) de substances qui remplissent la fonction de blocage métastatique des cellules néoplasiques qui ont survécu au traitement par le kit précité (2). Par rapport à des traitements connus de radiothérapie et de chimiothérapie dans le domaine du cancer, le complément selon l'invention permet d'augmenter l'efficacité de la thérapie, ce qui améliore considérablement les résultats thérapeutiques obtenus avec ou sans thérapies classiques et la qualité de vie du patient, et augmente les chances de survie. L'administration de ce complément, tout en maintenant la maladie sous contrôle, empêcherait le syndrome de lyse tumorale massive résultant souvent d'une chimiothérapie/radiothérapie, conduisant à une insuffisance fonctionnelle grave d'organes excréteurs (reins/foie) et à une insuffisance cardiaque, provoquant la mort du patient. Si le cancer devient une maladie chronique stable sous contrôle, les conséquences létales provoquées par une destruction néoplasique massive seront empêchées, ce qui permettra d'augmenter les chances de survie assortie d'une excellente qualité de vie.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: Italian (IT)